Skip to main content
APTAMER GROUP PLC logo

APTAMER GROUP PLC — Investor Relations & Filings

Ticker · APTA ISIN · GB00BNRRP542 LEI · 213800Y4XGH3WJNBE686 IL Professional, scientific and technical activities
Open in API
Filings indexed 202 across all filing types
Latest filing 2025-07-08 Regulatory Filings
Country GB United Kingdom
Listing IL APTA

About APTAMER GROUP PLC

https://aptamergroup.com/

Aptamer Group PLC is a life sciences company that develops custom affinity binders to address targeting challenges in research, diagnostics, and therapeutics. The company's core technology is the Optimer® platform, which discovers and develops proprietary, next-generation aptamer-based binders. These Optimer binders are engineered for high specificity, stability, and manufacturability. The company provides custom development services, partnering with global pharmaceutical, diagnostic, and biotechnology organizations to support their programs from early discovery through to clinical development. Key application areas include the development of novel therapeutics, advanced diagnostic assays, bioprocessing workflows, and biomarker discovery.

Recent filings

Filing Released Lang Actions
Posting of Circular and Notice of General Meeting
Regulatory Filings Classification · 98% confidence The document is a short announcement (under 5,000 characters) from Aptamer Group plc regarding the 'Posting of Circular and Notice of General Meeting'. It informs shareholders that the circular has been despatched and provides a link to the company's website to access the document. According to the 'Menu vs Meal' rule, since this is an announcement about the availability of a report/circular rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-07-08 English
Placing to raise £2.0 million
Capital/Financing Update Classification · 98% confidence The document is an official announcement from Aptamer Group PLC, identified by the RNS Number (7002P) and the date (04 July 2025). The core subject is a 'Placing to raise £2.0 million' through the issuance of new ordinary shares at a specific price. This activity—raising capital through the issuance of new shares to existing and new shareholders—directly corresponds to financing activities and capital structure changes. This fits the definition of 'Capital/Financing Update' (CAP). Although it involves issuing shares (which could relate to SHA), the primary purpose and focus of the announcement is the fundraising event itself, making CAP the most accurate classification. It is not a full annual report (10-K), an earnings release (ER), or a simple notice of dividend (DIV).
2025-07-04 English
Liver fibrosis breakthrough with Optimer® platform
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated June 30, 2025. It contains a headline announcing a 'Significant advance in liver fibrosis treatment' and details scientific milestones, market potential, and quotes from the CEO. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a general regulatory news service announcement, which is best classified as a Regulatory Filing (RNS) when it doesn't fit a more specific category like Earnings Release (ER) or Director's Dealing (DIRS). Since this is a scientific/pipeline update rather than a financial results announcement or a formal statutory report (like 10-K or IR), RNS is the most appropriate general regulatory category.
2025-06-30 English
Agreement with global life sciences leader
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number' and contains information typical of a regulatory news service announcement from the London Stock Exchange (LSE). The content details a 'new development and licensing agreement' with a life sciences partner, including specifics about product development, royalties, and management commentary. This is a general corporate announcement regarding a significant business event (a partnership/licensing deal) that is being disseminated via the RNS system. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific shareholder vote result (DVA), the most appropriate classification for a general, material, non-standard regulatory announcement distributed via RNS is the fallback category, Regulatory Filings (RNS). The document length is moderate, but the content is purely an announcement of a transaction, not the underlying detailed report itself.
2025-06-25 English
Unilever second Optimer development programme
Regulatory Filings Classification · 100% confidence The document is identified by the header 'RNS Number : 6900K' and contains an announcement dated May 30, 2025, regarding a new development program with Unilever. The text describes a business development/collaboration update, specifically a fee-for-service agreement for developing Optimer binders. This type of announcement, which details business progress, partnerships, and commercial updates, is typically classified as a general regulatory announcement or news release, especially when distributed via RNS (Regulatory News Service). Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a specific corporate action like a dividend (DIV) or share transaction (POS), the most appropriate category is the general regulatory filing/announcement fallback, RNS. The document length (5749 chars) is substantial enough that it is the announcement itself, not just a brief notice of publication (RPA).
2025-05-30 English
Aptamer Announces New Data at ASGCT
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated, indicating it is a regulatory announcement distributed via the RNS service of the London Stock Exchange. The content announces new scientific data presented at a conference ('Aptamer Announces New Data at ASGCT') regarding their Optimer delivery vehicle. This is a specific operational update concerning scientific progress and potential commercial applications, rather than a formal financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). Since it is a general, time-sensitive announcement distributed through the official regulatory news service (RNS) that doesn't fit neatly into the other specific categories (like ER, CT, or CAP), it defaults to the general regulatory filing category.
2025-05-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.